{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Hernaez R"],"funding":["Veterans Administration Medical Center","Univerzita Karlova v Praze","Center for Geosphere Dynamics, Charles University","National Institute of Diabetes and Digestive and Kidney Diseases","NIDDK NIH HHS","VA HSR&D","Center for Innovations in Quality, Effectiveness and Safety","National Cancer Institute","NCI NIH HHS","National Institutes of Health","Cancer Prevention and Research Institute of Texas"],"pagination":["717-727"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12036733"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["79(3)"],"pubmed_abstract":["Background & aims
Twenty-eight-day mortality ranges from 30-90% in patients with acute-on-chronic liver failure grades 2/3 (severe ACLF). Though liver transplantation (LT) has demonstrated a survival benefit, the scarcity of donor organs and uncertainty regarding post-LT mortality among patients with severe ACLF may cause hesitancy. We developed and externally validated a model to predict 1-year post-LT mortality in severe ACLF, called the Sundaram ACLF-LT-Mortality (SALT-M) score, and estimated the median length of stay (LoS) after LT (ACLF-LT-LoS).Methods
In 15 LT centers in the US, we retrospectively identified a cohort of patients with severe ACLF transplanted between 2014-2019, followed up to Jan'2022. Candidate predictors included demographics, clinical and laboratory"],"journal":["Journal of hepatology"],"pubmed_title":["The novel SALT-M score predicts 1-year post-transplant mortality in patients with severe acute-on-chronic liver failure."],"pmcid":["PMC12036733"],"funding_grant_id":["CIN 13-413","U01 CA230997","R01 CA186566","NCI U01 CA230997","U01 CA230690","K08 DK124577","P30 DK056338","RP150587","R01CA186566","P30 DK 56338","U01CA230690","K08-DK124577","U01 CA230694"],"pubmed_authors":["Gao J","Sundaram V","Karvellas CJ","Patel P","Boike JR","Lin MV","Mahmud N","Xue P","Rahimi RS","Wu T","Jalal PK","Fortune BE","Al Attar A","Vyhmeister R","Jalan R","Shetty K","Simonetto DA","Multi-Organ Dysfunction and Evaluation for Liver Transplantation (MODEL) Consortium","Garcia R","Hurtado M","Reddy V","Jou JH","Winters AC","Ying X","Simpson MA","Artzner T","Lopez CR","Khemichian S","Sacleux SC","Kriss MS","Liu Y","Kuo A","Hernaez R","Salmastyan G","Kosari K","Cholankeril G","Mishra S","Parks M","Saliba F","Mohamed I","Flocco G","Kanwal F","Im GY","Lindenmeyer CC","Thanneeru P","Campbell B","Stein LL","Izzy M","Cranford W"],"additional_accession":[]},"is_claimable":false,"name":"The novel SALT-M score predicts 1-year post-transplant mortality in patients with severe acute-on-chronic liver failure.","description":"Background & aims
Twenty-eight-day mortality ranges from 30-90% in patients with acute-on-chronic liver failure grades 2/3 (severe ACLF). Though liver transplantation (LT) has demonstrated a survival benefit, the scarcity of donor organs and uncertainty regarding post-LT mortality among patients with severe ACLF may cause hesitancy. We developed and externally validated a model to predict 1-year post-LT mortality in severe ACLF, called the Sundaram ACLF-LT-Mortality (SALT-M) score, and estimated the median length of stay (LoS) after LT (ACLF-LT-LoS).Methods
In 15 LT centers in the US, we retrospectively identified a cohort of patients with severe ACLF transplanted between 2014-2019, followed up to Jan'2022. Candidate predictors included demographics, clinical and laboratory","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Sep","modification":"2025-07-03T03:04:35.031Z","creation":"2025-07-03T03:04:35.031Z"},"accession":"S-EPMC12036733","cross_references":{"pubmed":["37315809"],"doi":["10.1016/j.jhep.2023.05.028"]}}